Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

BACKGROUND: Following the increased survival of patients with metastatic melanoma thanks to immunotherapy and targeted therapy, neoadjuvant approaches are being investigated to address the unmet needs of unresponsive and intolerant patients. We aim to investigate the efficacy of neoadjuvant plus adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Cioli, Eleonora, Chiarion-Sileni, Vanna, Quaglino, Pietro, Spagnolo, Francesco, Guidoboni, Massimo, Del Vecchio, Michele, Peris, Ketty, Queirolo, Paola, Fioretto, Luisa, Caracò, Corrado, Paone, Miriam, Sorrentino, Antonio, Capone, Mariaelena, Giannarelli, Diana, Ferrara, Gerardo, Massi, Daniela, Trojaniello, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949553/
https://www.ncbi.nlm.nih.gov/pubmed/36845751
http://dx.doi.org/10.3389/fonc.2023.1107307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949553/
https://www.ncbi.nlm.nih.gov/pubmed/36845751
http://dx.doi.org/10.3389/fonc.2023.1107307

Ejemplares similares